产品
编 号：F136349
分子式：C26H38ClNO4
分子量：464.04
分子式：C26H38ClNO4
分子量：464.04
产品类型
规格
价格
是否有货
1mg
询价
询价
5mg
询价
询价
结构图
CAS No: 1356447-90-9
产品详情
生物活性：
GZ-793A is an orally active and selective vesicular monoamine transporter-2 (VMAT2) inhibitor, with an Ki of 0.029 μM. GZ-793A inhibits the neurochemical effects of methamphetamine (METH)-induced dopamine release. GZ-793A can be used for research of METH addiction.
体内研究：
GZ-793A (30, 60, 120 or 240 mg/kg; p.o.; once) decreases the number of METH infusions self-administered across each time interval evaluats in a dose-dependent manner.GZ-793A (1-100 μM; 90 min) inhibits METH (5 μM)-evoked fractional dopamine releases.Animal Model:Adult male Sprague-Dawley rats.
Dosage:30, 60, 120 or 240 mg/kg
Administration:Oral administration; once.
Result:Decreased the number of METH infusions self-administered in a dose-dependent manner, and with an ~85% reduction at the highest dose (240 mg/kg).Decreased the METH self-administration produced by lasted at least 180 min.
Animal Model:Male Sprague-Dawley rats (250–275 g; 9-week-old; 0.5 mm thick rats coronal striatal slices are used).
Dosage:1-100 μM
Administration:90 min
Result:Inhibited methamphetamine-evoked dopamine released in a concentration-dependent manner.
GZ-793A is an orally active and selective vesicular monoamine transporter-2 (VMAT2) inhibitor, with an Ki of 0.029 μM. GZ-793A inhibits the neurochemical effects of methamphetamine (METH)-induced dopamine release. GZ-793A can be used for research of METH addiction.
体内研究：
GZ-793A (30, 60, 120 or 240 mg/kg; p.o.; once) decreases the number of METH infusions self-administered across each time interval evaluats in a dose-dependent manner.GZ-793A (1-100 μM; 90 min) inhibits METH (5 μM)-evoked fractional dopamine releases.Animal Model:Adult male Sprague-Dawley rats.
Dosage:30, 60, 120 or 240 mg/kg
Administration:Oral administration; once.
Result:Decreased the number of METH infusions self-administered in a dose-dependent manner, and with an ~85% reduction at the highest dose (240 mg/kg).Decreased the METH self-administration produced by lasted at least 180 min.
Animal Model:Male Sprague-Dawley rats (250–275 g; 9-week-old; 0.5 mm thick rats coronal striatal slices are used).
Dosage:1-100 μM
Administration:90 min
Result:Inhibited methamphetamine-evoked dopamine released in a concentration-dependent manner.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备